GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$6.91
-0.11 (-1.57%)
▼
5d:
+3.44%
30d:
+14.98%
90d:
+11.81%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GYRE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GYRE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $6.91, which is considered extended relative to its 30-day fair value range of $5.93 to $6.77. From a valuation perspective, the stock is trading at a discount (Forward PE: -29.4) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a downtrend. Immediate support is located at $6.31, while resistance sits at $7.29.
Market Sentiment: GYRE scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.67 (+170.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GYRE is in a downtrend. Immediate support is located at $6.31, while resistance sits at $7.29.
Market Sentiment: GYRE scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.67 (+170.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.93 -
$6.77
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 170.1% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.93 -
$6.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.31
Resistance Level
$7.29
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.40
Wall Street Target
$18.67
(+170.1%)
Revenue Growth (YoY)
-2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-19.3%
PE vs Historical
-29.4 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 8:36 AM ET
Data refreshes hourly during market hours. Next update: 9:36 AM
Data refreshes hourly during market hours. Next update: 9:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
